Treatment with budesonide/formoterol pressurized metered-dose inhaler in patients with asthma: a focus on patient-reported outcomes
Richard D O'ConnorSharp Rees-Stealy Medical Group, San Diego, CA, USAAbstract: In the United States, budesonide/formoterol pressurized metered-dose inhaler (pMDI) is approved for treatment of asthma in patients aged ≥12 years whose asthma is not adequately controlled with an i...
Main Author: | Richard D O'Connor |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2011-01-01
|
Series: | Patient Related Outcome Measures |
Online Access: | http://www.dovepress.com/treatment-with-budesonideformoterol-pressurized-metered-dose-inhaler-i-a6169 |
Similar Items
-
Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
by: Nicola A. Hanania, et al.
Published: (2020-04-01) -
COMPARATIVE EFFICACY OF INHALED DRUGS FORMOTEROL / BECLOMETHASONE AND FORMOTEROL / BUDESONIDE AND BRONCHIAL ASTHMA
by: V. A. Nikitin, et al.
Published: (2016-03-01) -
Long-term maintenance of pediatric asthma: focus on budesonide/formoterol inhalation aerosol
by: Peter N Huynh, et al.
Published: (2010-02-01) -
Exposure-Response and Clinical Outcome Modeling of Inhaled Budesonide/Formoterol Combination in Asthma Patients
by: Hyun-moon Back, et al.
Published: (2020-04-01) -
The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada
by: Mohsen Sadatsafavi, et al.
Published: (2021-10-01)